

Emanuele Pontali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2914654/publications.pdf>

Version: 2024-02-01

88
papers

2,781
citations

159358

30
h-index

189595

50
g-index

91
all docs

91
docs citations

91
times ranked

3610
citing authors

#	ARTICLE	IF	CITATIONS
1	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	1.5	18
2	Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study. <i>Liver International</i> , 2021, 41, 271-275.	1.9	12
3	HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C. <i>International Journal of Drug Policy</i> , 2021, 90, 103055.	1.6	31
4	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1217-1225.	1.5	61
5	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. <i>Pulmonology</i> , 2021, 27, 248-256.	1.0	18
6	<i>Mycobacterium Kansasii</i> infection in a psoriasis patient treated with adalimumab and switch to apremilast: first report and literature review. <i>Dermatology Reports</i> , 2021, 13, 8797.	0.4	1
7	Chronic Viral Hepatitis in the Italian Prison Setting: Prevalence, Outcomes, Literature Needs and Perspectives. <i>Healthcare (Switzerland)</i> , 2021, 9, 1186.	1.0	6
8	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	2.2	121
9	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. <i>Antibiotics</i> , 2021, 10, 1355.	1.5	5
10	Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. <i>International Journal of Infectious Diseases</i> , 2020, 92, 62-68.	1.5	13
11	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	1.2	15
12	Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 213-215.	1.5	115
13	COVID-19 in a Patient with β^0 -Thalassemia Major and Severe Pulmonary Arterial Hypertension. <i>Hemoglobin</i> , 2020, 44, 218-220.	0.4	9
14	Tuberculosis in the time of COVID-19: quality of life and digital innovation. <i>European Respiratory Journal</i> , 2020, 56, 2001998.	3.1	28
15	Evaluation of novel coronavirus disease (COVID-19) using quantitative lung CT and clinical data: prediction of short-term outcome. <i>European Radiology Experimental</i> , 2020, 4, 39.	1.7	48
16	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	3.1	89
17	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	1.5	126
18	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2734.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. <i>Patient</i> , 2020, 13, 375-387.	1.1	5
20	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	1.7	30
21	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	3.1	113
22	Burden and Characteristics of the Comorbidity Tuberculosisâ€”Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy337.	0.4	12
23	Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. <i>European Respiratory Review</i> , 2019, 28, 190035.	3.0	107
24	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	1.5	41
25	Recent evidence on delamanid use for rifampicin-resistant tuberculosis. <i>Journal of Thoracic Disease</i> , 2019, 11, S457-S460.	0.6	9
26	Challenging MDR-TB clinical problems â€” The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. <i>International Journal of Infectious Diseases</i> , 2019, 80, S68-S72.	1.5	21
27	The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines. <i>European Respiratory Journal</i> , 2019, 54, 1901272.	3.1	30
28	Long-term safety and efficacy of dolutegravir and unboosted atazanavir among experienced HIV-infected adults. <i>Aids</i> , 2019, 33, 2446-2447.	1.0	1
29	Multi and extensively drug-resistant pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 244-252.	1.2	21
30	Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing. <i>ERJ Open Research</i> , 2018, 4, 00108-2017.	1.1	5
31	Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy. <i>International Journal of Drug Policy</i> , 2018, 59, 50-53.	1.6	33
32	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800934.	3.1	59
33	The cursed duet today: Tuberculosis and HIV-coinfection. <i>Presse Medicale</i> , 2017, 46, e23-e39.	0.8	50
34	Hospital admissions for HIV-infected prisoners in Italy. <i>International Journal of Prisoner Health</i> , 2017, 13, 105-112.	0.5	3
35	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	3.1	233
36	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. <i>European Respiratory Journal</i> , 2017, 49, 1700146.	3.1	59

#	ARTICLE	IF	CITATIONS
37	Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel. <i>Infection</i> , 2017, 45, 131-138.	2.3	15
38	Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. <i>Respiratory Medicine</i> , 2017, 132, 68-75.	1.3	7
39	Control of the HIV-1 DNA Reservoir Is Associated <i>In Vivo</i> and <i>In Vitro</i> with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. <i>Journal of Virology</i> , 2017, 91, .	1.5	39
40	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1489-1490.	2.5	2
41	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2017, 50, 1701462.	3.1	103
42	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017, 23, 1718-1721.	2.0	43
43	Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 341.	1.8	47
44	Post-implementation blues: the unfulfilled potential of Xpert. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1073-1073.	0.6	1
45	Blood-borne viral co-infections among human immunodeficiency virus-infected inmates. <i>International Journal of Prisoner Health</i> , 2016, 12, 88-97.	0.5	6
46	Unusual Presentation of Human Immunodeficiency Virus-Related Kaposi's Sarcoma. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1169-1170.	0.5	1
47	Advancing global programmatic management of latent tuberculosis infection for at risk populations. <i>European Respiratory Journal</i> , 2016, 47, 1327-1330.	3.1	22
48	New anti-tuberculosis drugs for special populations: a difficult-to-address issue. <i>European Respiratory Journal</i> , 2016, 48, 957-958.	3.1	5
49	Recent developments in the diagnosis and management of tuberculosis. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16078.	1.1	58
50	Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy. <i>Medicine (United States)</i> , 2016, 95, e5257.	0.4	10
51	WHO strategies for the programmatic management of drug-resistant tuberculosis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 991-1002.	1.0	34
52	Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2016, 47, 394-402.	3.1	136
53	Cytopenias during Treatment of HIV-HCV-Coinfection with Pegylated Interferon and Ribavirin: Safety Analysis of the OPERA Study. <i>Antiviral Therapy</i> , 2015, 20, 39-48.	0.6	2
54	Multidrug-Resistant Tuberculosis in Europe, 2010-2011. <i>Emerging Infectious Diseases</i> , 2015, 21, 409-416.	2.0	75

#	ARTICLE	IF	CITATIONS
55	New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Research, 2015, 1, 00010-2015.	1.1	65
56	Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. European Respiratory Journal, 2015, 45, 25-29.	3.1	76
57	Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2015, 13, 305-315.	2.0	39
58	Effect of Aging, Glucose Level, and HIV Viral Load on Response to Treatment with Pegylated Interferon Plus Ribavirin in HIV/HCV Co-Infected Women. Journal of Women's Health, 2015, 24, 159-164.	1.5	0
59	Management of drug resistant TB in patients with HIV co-infection. Expert Opinion on Pharmacotherapy, 2015, 16, 2737-2750.	0.9	10
60	Specific Issues in the Management of Hepatocellular Carcinoma in Hepatitis B Virus/Hepatitis C Virus-Human Immunodeficiency Virus Co-infected Patients. International STD Research & Reviews, 2015, 3, 69-83.	0.2	3
61	Unusual Presentation of Visceral Leishmaniasis in an HIV-Infected Patient. AIDS Research and Human Retroviruses, 2014, 30, 846-847.	0.5	2
62	Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV/HIV Coinfection in Interferon-Naive Patients. Antiviral Therapy, 2014, 19, 735-745.	0.6	5
63	A new paradigm for multidrug-resistant tuberculosis?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 884-884.	0.6	1
64	An unexpected Streptococcus pneumoniae strain. Journal of Chemotherapy, 2014, 26, 173-175.	0.7	0
65	Drug-resistant tuberculosis. Current Opinion in Pulmonary Medicine, 2013, 19, 266-272.	1.2	42
66	Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11970-11975.	3.3	73
67	Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2012, 10, 1109-1115.	2.0	11
68	TB in migrants. , 2012, , 194-205.		0
69	Editorial [Hot Topic: The Evolving Challenges in Pediatric HIV Management (Guest Editors: Emanuele Tj ETQq1 1 0.784314 rgBT /Ove	0.4	0
70	Improving Adherence to Combination Antiretroviral Therapy in Children with HIV Infection: Challenges and Possibilities. Current Pediatric Reviews, 2011, 7, 199-211.	0.4	0
71	Management of MDR-TB household contacts: how difficult is it to climb the mountain? [Editorial]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1137-1138.	0.6	1
72	Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India. PLoS ONE, 2011, 6, e28066.	1.1	71

#	ARTICLE	IF	CITATIONS
73	Tick-Borne Encephalitis (TBE) During a "Grand Tour" of Europe Clinically Manifesting in a TBE-Free Region. <i>Journal of Travel Medicine</i> , 2010, 17, 143-145.	1.4	8
74	<i>Erysipelothrix rhusiopathiae</i> intra-abdominal abscess. <i>International Journal of Infectious Diseases</i> , 2010, 14, e81-e83.	1.5	12
75	HIV-1 diversity among inmates of Italian prisons. <i>Journal of Medical Virology</i> , 2008, 80, 1689-1694.	2.5	3
76	Imported Typhoid Fever With Hepatitis From Bangladesh: A Case of Delayed Response to Ceftriaxone?. <i>Journal of Travel Medicine</i> , 2008, 15, 366-368.	1.4	3
77	Prevalence of Hepatitis B virus and/or Hepatitis C virus co-infections in prisoners infected with the Human Immunodeficiency Virus. <i>International Journal of Prisoner Health</i> , 2008, 4, 77-82.	0.5	14
78	Interactions of Antiretroviral Drugs with Anti-Infectives and Other Antiretrovirals. <i>Chemotherapy</i> , 2007, 53, 26-29.	0.8	9
79	Antiretroviral Treatment in Correctional Facilities. <i>HIV Clinical Trials</i> , 2005, 6, 25-37.	2.0	30
80	Facilitating Adherence to Highly Active Antiretroviral Therapy in Children with HIV Infection. <i>Paediatric Drugs</i> , 2005, 7, 137-149.	1.3	38
81	Contemporary and Emerging Drug Treatments for Urinary Incontinence in Children. <i>Paediatric Drugs</i> , 2005, 7, 151-162.	1.3	34
82	Antiretroviral Treatment in Resource-limited Settings. <i>Journal of Health Management</i> , 2003, 5, 315-326.	0.4	1
83	Analysis of the antigen specific T cell repertoires in HIV infection. <i>Immunology Letters</i> , 2001, 79, 85-91.	1.1	7
84	Active Hepatitis G Virus Infection in Perinatally HIV-Infected Children. <i>HIV Clinical Trials</i> , 2001, 2, 387-389.	2.0	7
85	Adherence to Combination Antiretroviral Treatment in Children. <i>HIV Clinical Trials</i> , 2001, 2, 466-473.	2.0	26
86	Compliance to combination antiretroviral therapy in HIV-1 infected children. <i>International Journal of Antimicrobial Agents</i> , 2000, 16, 371-372.	1.1	19
87	Does HCV "HIV co-infection exist?. <i>International Journal of Antimicrobial Agents</i> , 2000, 16, 349-351.	1.1	3
88	Nutritional status changes in HIV-infected children receiving combined antiretroviral therapy including protease inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2000, 16, 365-369.	1.1	6